Shi Zhongju, Zhou Hengxing, Pan Bin, Lu Lu, Liu Jun, Kang Yi, Yao Xue, Feng Shiqing
Department of Orthopaedics, Tianjin Medical University General Hospital, Tianjin, PR China.
PLoS One. 2016 Dec 20;11(12):e0168691. doi: 10.1371/journal.pone.0168691. eCollection 2016.
Nowadays, the efficacy of teriparatide in treating osteoporosis was widely accepted, but the discussion about using teriparatide to enhance fracture healing hasn't come to an agreement. This meta-analysis was conducted to evaluate the effectiveness of teriparatide for fracture healing.
We searched PubMed, the Cochrane Library, and Embase in August 2016 for randomized controlled trials (RCTs) which concerned the treatment of teriparatide for fracture healing.
Finally, a total of 380 patients were randomly assigned in the 5 trials included in this meta-analysis. There was a significant effectiveness with regards to function improvement in patients following fracture, however, there was no significant effectiveness with regards to time of radiographic fracture healing, fracture healing rate and reduction in pain.
This analysis showed that administration of teriparatide following fracture lacked the effectiveness for fracture healing. Moreover, teriparatide administration had no apparent adverse effects. These results should be interpreted with caution because of some clear limitations. If we want to confirm whether teriparatide improves fracture healing, more high-quality randomized controlled trials are needed.
目前,特立帕肽治疗骨质疏松症的疗效已被广泛认可,但关于使用特立帕肽促进骨折愈合的讨论尚未达成共识。本荟萃分析旨在评估特立帕肽对骨折愈合的有效性。
2016年8月,我们检索了PubMed、Cochrane图书馆和Embase,以查找有关特立帕肽治疗骨折愈合的随机对照试验(RCT)。
最终,本荟萃分析纳入的5项试验中共有380例患者被随机分组。骨折后患者的功能改善有显著效果,然而,在影像学骨折愈合时间、骨折愈合率和疼痛减轻方面没有显著效果。
该分析表明,骨折后给予特立帕肽对骨折愈合缺乏有效性。此外,给予特立帕肽没有明显的不良反应。由于存在一些明显的局限性,这些结果应谨慎解读。如果我们想确认特立帕肽是否能改善骨折愈合,还需要更多高质量的随机对照试验。